Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Latest action · Nov 3, 2026 Became Public Law No: 119-138.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 6, 2026
- Passed HouseJul 22, 2026
- Passed SenateSep 28, 2026
- To the PresidentOct 26, 2026
- Became lawNov 3, 2026Public Law 119-138
Summary
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
The act reauthorizes
- grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
- grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
- a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.
Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.
Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
Cosponsors 103
Members who signed on, in the order they did. Signatures ran from Apr 6, 2026 to Jul 9, 2026; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-CA | Ken Calvert | Original | Apr 6, 2026 |
| D-MN | Angie Craig | Apr 9, 2026 | |
| R-PA | Brian K. Fitzpatrick | Apr 9, 2026 | |
| D-MA | Jake Auchincloss | Apr 9, 2026 | |
| D-IL | Janice D. Schakowsky | Apr 9, 2026 | |
| R-TX | Michael T. McCaul | Apr 9, 2026 | |
| R-TN | Scott DesJarlais | Apr 9, 2026 | |
| D-IL | Bradley Scott Schneider | Apr 14, 2026 | |
| R-CA | David G. Valadao | Apr 14, 2026 | |
| R-PA | Glenn Thompson | Apr 14, 2026 | |
| D-WI | Gwen Moore | Apr 14, 2026 | |
| D-CO | Jason Crow | Apr 14, 2026 | |
| R-CO | Jeff Hurd | Apr 14, 2026 | |
| R-OH | David P. Joyce | Apr 15, 2026 | |
| D-TX | Marc A. Veasey | Apr 15, 2026 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 6, 2026Markup May 21, 2026Reported Jul 9, 2026 |
| Health Subcommittee | Referred Apr 6, 2026Markup May 13, 2026Reported May 13, 2026 |
Actions 22
Everything that happened, newest first.
- Nov 3, 2026Became Public Law No: 119-138.
- Nov 3, 2026Signed by President.
- Oct 26, 2026Presented to President.
- Oct 14, 2026Message on Senate action sent to the House.
- Sep 28, 2026Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
- Jul 23, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026Considered as unfinished business. (consideration: CR H5159)
- Jul 22, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
- Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 9, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
- Jul 9, 2026Placed on the Union Calendar, Calendar No. 637.
- May 21, 2026Committee Consideration and Mark-up Session Held
- May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
- May 13, 2026Subcommittee Consideration and Mark-up Session Held
- May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- Apr 6, 2026Referred to the Subcommittee on Health.
- Apr 6, 2026Introduced in House
- Apr 6, 2026Referred to the House Committee on Energy and Commerce.
In the Congressional Record 3
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S5146, S5147 | Christopher A. Coons D-DE, Lisa Murkowski R-AK | Sep 29, 2026 |
| Senate | Debate and remarks S5120 | Mike Lee R-UT | Sep 28, 2026 |
| House | Debate and remarks H4652–H4654Text printed H4653 | Brett Guthrie R-KY, Diana DeGette D-CO, Ken Calvert R-CA, Mike Quigley D-IL | Jul 20, 2026 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Committee report
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 172, no. 62, April 6, 2026, page H2825.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 4472 | Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 | Related bill | Aug 10, 2026 |
Titles 7
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
- Short Title(s) as Introduced
- Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Short Title(s) as Reported to House
- Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Short Title(s) as Passed House
- Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Short Titles from ENR (Enrolled) bill text
- Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Short Title(s) from PCS (Placed on Senate Calendar) bill text
- Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Official Title from EH (Engrossed in House) bill text
- To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Department of Health and Human Services
- Drug therapy
- Food and Drug Administration (FDA)
- Government information and archives
- Health
- Health programs administration and funding
- Internet, web applications, social media
- Medical research
- National Institutes of Health (NIH)
- Neurological disorders
- Public-private cooperation
- Research administration and funding
Text 5
Each version as it was printed, newest first.
- —Enrolled Bill
- Jul 23, 2026Placed on Calendar Senate
- Jul 22, 2026Engrossed in House
- Jul 9, 2026Reported in House
- Apr 6, 2026Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
